Apoptic Biomarkers of Periodontal Disease

This study has been completed.

Sponsor:

Information provided by:

University of Michigan

ClinicalTrials.gov Identifier:

NCT00569075

First received: December 5, 2007

Last updated: May 9, 2017

Last verified: May 2017

History of Changes

Purpose

The goal of this study is to facilitate early diagnosis of gum disease. Proteins associated with cell death will be isolated from gum pockets of diseased and healthy patients and evaluated.

Condition	Intervention
Periodontitis	Other: collection of gingival crevicular fluid


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Apoptotic Biomarkers of Periodontal Disease

Resource links provided by NLM:

MedlinePlus related topics: Gum Disease

U.S. FDA Resources

Further study details as provided by University of Michigan:

Biospecimen Retention: Samples Without DNA

saliva and plaque


Enrollment:	60
Study Start Date:	October 2006
Study Completion Date:	October 2009
Primary Completion Date:	October 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
High Risk High risk disease prone population	Other: collection of gingival crevicular fluid GCF samples will be collected at 3 month intervals
Low Risk Low risk disease population	Other: collection of gingival crevicular fluid GCF samples will be collected at 3 month intervals

Detailed Description:

Early detection of the progression of periodontitis is difficult because it typically relies on comparisons of clinical measurements made with a calibrated probe and nonstandardized radiographs over time. Both methods detect periodontal breakdown only after it has occurred. Therefore, considerable emphasis has been placed on identifying more specific and sensitive methods to diagnose and detect periodontal disease progression. The overall goal of this project is to determine whether specific apoptosis-associated proteins, specifically fibronectin (FN) fragments, caspase-3, soluble Fas, and soluble Fas ligand, sampled from gingival crevicular fluid (GCF) can be used as markers for periodontal disease progression.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

healthy adults with healthy gums or those with periodontitis

Criteria

Inclusion Criteria:

Adults over age of 18
Healthy or diagnosis of periodontitis

Exclusion Criteria:

Active treatment with anti-inflammatory agents such as NSAIDs or steroids and pregnant females

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00569075

Locations


United States, Michigan
Michigan Center for Oral Health Research
Ann Arbor, Michigan, United States, 48106

Sponsors and Collaborators

University of Michigan

Investigators


Principal Investigator:	Yvonne Kapila, DDS, PhD	University of Michigan

More Information


Responsible Party:	Yvonne Kapila, University of Michigan
ClinicalTrials.gov Identifier:	NCT00569075 History of Changes
Other Study ID Numbers:	2004-04
Study First Received:	December 5, 2007
Last Updated:	May 9, 2017

Keywords provided by University of Michigan:


Apoptic biomarkers Early detection periodontitis Gingival crevicular fluid Healthy subjects

Additional relevant MeSH terms:


Periodontitis Periodontal Diseases Gingival Diseases Mouth Diseases Stomatognathic Diseases

ClinicalTrials.gov processed this record on June 23, 2017

To Top